Rizatriptan in the treatment of migraine

References

• AdelmanJULiptonRBFerrariMD2001Comparison of rizatriptan and other triptans on stringent measures of efficacyNeurology5713778311673575
   PubMed Web of Science ®Google Scholar
• AdelmanJUMannixLKVon SeggernRL2000Rizatriptan tablet vs wafer: patient preferenceHeadache40371210849030
   PubMed Web of Science ®Google Scholar
• AhrensSPFarmerMVWilliamsDL1999Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study GroupCephalalgia195253010403069
   PubMed Web of Science ®Google Scholar
• BelseyJD2004Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trialsCurr Med Res Opin206596915140331
   PubMed Web of Science ®Google Scholar
• BergJStovnerLJ2005Cost of migraine and other headaches in EuropeEur J Neurol12Suppl 1596215877781
   PubMed Web of Science ®Google Scholar
• BianchiGPassoniAGriffiniPL1989Effects of a new calcium antagonist, Rec 15/2375, on cardiac contractility of conscious rabbitsPharmacol Res211932002748506
   PubMed Web of Science ®Google Scholar
• BlockGAGoldsteinJPolisA1998Efficacy and safety of rizatriptan vs standard care during long-term treatment for migraine. Rizatriptan Multicenter Study GroupsHeadache387647111284464
   PubMed Web of Science ®Google Scholar
• BomhofMPazJLeggN1999Comparison of rizatriptan 10 mg vs naratriptan 2.5 mg in migraineEur Neurol42173910529545
   PubMed Web of Science ®Google Scholar
• [BASH] British Association for the Study of Headache2004Guidelines for all doctors in the diagnosis and management of migraine and tension-type headache2nd ed [online] Accessed 19 September 2005 URL: http://www.bash.org.uk/
   Google Scholar
• BussoneGD’AmicoDMcCarrollKA2002Restoring migraine sufferers’ ability to function normally: a comparison of rizatriptan and other triptans in randomized trialsEur Neurol48172712373035
   PubMed Web of Science ®Google Scholar
• CadyRCrawfordGAhrensS2001Long-term efficacy and tolerability of rizatriptan wafers in migraine [online]Med Gen Med34 URL: http://www.medscape.com/viewarticle/408137
   Google Scholar
• Ceballos HernansanzMASanchezRRCanoOrg2003Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectivenessClin Ther2520536912946550
   PubMed Web of Science ®Google Scholar
• ChengHPolvinoWJSciberrasD1996Pharmacokinetics and food interaction of MK-462 in healthy malesBiopharm Drug Dispos1717248991488
   PubMed Web of Science ®Google Scholar
• ChristieSGobelHMateosV2003Crossover comparison of efficacy and preference for rizatriptan 10 mg vs ergotamine/caffeine in migraineEur Neurol4920912464714
   PubMed Web of Science ®Google Scholar
• CumberbatchMJHillRGHargreavesRJ1997Rizatriptan has central antinociceptive effects against durally evoked responsesEur J Pharmacol32837409203565
   PubMed Web of Science ®Google Scholar
• CutlerNRJheeSSMajumdarAK1999Pharmacokinetics of rizatriptan tablets during and between migraine attacksHeadache39264915613223
   PubMed Web of Science ®Google Scholar
• CutrerFMGoadsbyPJFerrariMD2004Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project)Clin Ther2615334515531016
   PubMed Web of Science ®Google Scholar
• DahlofCGLiptonRBMcCarrollKA2000Within-patient consistency of response of rizatriptan for treating migraineNeurology551511611094106
   PubMed Web of Science ®Google Scholar
• DodickDLiptonRBMartinV2004Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraineHeadache444142515147249
   PubMed Web of Science ®Google Scholar
• FerrariMDGoadsbyPJLiptonRB2005The use of multiattribute decision models in evaluating triptan treatment options in migraineJ Neurol25210263215761676
   PubMed Web of Science ®Google Scholar
• FerrariMDGoadsbyPJRoonKI2002Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trialsCephalalgia226335812383060
   PubMed Web of Science ®Google Scholar
• FerrariMDLoderEMcCarrollKA2001Meta-analysis of rizatriptan efficacy in randomized controlled clinical trialsCephalalgia211293611422095
   PubMed Web of Science ®Google Scholar
• GerthWCSarmaSHuXH2004Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and modelJ Occup Environ Med46485414724478
   PubMed Web of Science ®Google Scholar
• GijsmanHKramerMSSargentJ1997Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraineCephalalgia17647519350384
   PubMed Web of Science ®Google Scholar
• GoadsbyPJHargreavesRJ2000Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptanNeurology55S81411089513
   PubMed Web of Science ®Google Scholar
• GoadsbyPJLiptonRBFerrariMD2002Migraine – current understanding and treatmentN Engl J Med3462577011807151
   PubMed Web of Science ®Google Scholar
• GöbelHHeinzeAHeinze-KuhnK2001Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70527 patient episodesHeadache412647011264686
   PubMed Web of Science ®Google Scholar
• GoldbergMRLeeYVyasKP2000Rizatriptan, a novel 5-HT1B/1D agonist for migraine: single- and multiple-dose tolerability and pharmacokinetics in healthy subjectsJ Clin Pharmacol40748310631625
   PubMed Web of Science ®Google Scholar
• GoldbergMRSciberrasDDe SmetM2001Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprololBr J Clin Pharmacol52697611453892
   PubMed Web of Science ®Google Scholar
• GoldsteinJRyanRJiangK1998Crossover comparison of rizatriptan 5 mg and 10 mg vs sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study GroupHeadache387374711284462
   PubMed Web of Science ®Google Scholar
• GoriSMorelliNBelliniG2005Rizatriptan does not change cerebral blood flow velocity during migraine attacksBrain Res Bull6529730015811594
   PubMed Web of Science ®Google Scholar
• [HCS] Headache Classification Subcommittee of the International Headache Society2004The International Classification of Headache Disorders, 2nd edCephalalgia24Suppl 1916014979299
   PubMed Web of Science ®Google Scholar
• HuXHMarksonLELiptonRB1999Burden of migraine in the United States: disability and economic costsArch Intern Med159813810219926
   PubMed Web of Science ®Google Scholar
• JamiesonDCutrerFMGoldsteinJ2003Real-world experiences in migraine therapy with rizatriptanHeadache432233012603640
   PubMed Web of Science ®Google Scholar
• KolodnyAPolisABattistiWP2004Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tabletsCephalalgia24540615196296
   PubMed Web of Science ®Google Scholar
• KramerMSMatzura-WolfeDPolisA1998A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study GroupNeurology51773819748025
   PubMed Web of Science ®Google Scholar
• LáinezMJLopezAPascualAM2005Effects on productivity and quality of life of rizatriptan for acute migraine: a workplace studyHeadache458839015985105
   PubMed Web of Science ®Google Scholar
• LeeYConroyJAStepanavageME1999Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteersBr J Clin Pharmacol47373810233200
   PubMed Web of Science ®Google Scholar
• LeiraRDualdeEdel BarrioH2003Almotriptan vs rizatriptan in patients with migraine in SpainHeadache437344112890128
   PubMed Web of Science ®Google Scholar
• LiptonRBBigalME2005Migraine: epidemiology, impact, and risk factors for progressionHeadache45Suppl 1S31315833088
   PubMed Web of Science ®Google Scholar
• LiptonRBBigalMEKolodnerK2003The family impact of migraine: population-based studies in the USA and UKCephalalgia234294012807522
   PubMed Web of Science ®Google Scholar
• LiptonRBCutrerFMGoadsbyPJ2005How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physiciansCurr Med Res Opin214132415811210
   PubMed Web of Science ®Google Scholar
• LiptonRBHamelskySWDaynoJM2002What do patients with migraine want from acute migraine treatment?Headache42Suppl 13911966858
   PubMed Web of Science ®Google Scholar
• LiptonRBPascualJGoadsbyPJ2001aEffect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysisHeadache417546311576198
   PubMed Web of Science ®Google Scholar
• LiptonRBStewartWF1999Acute migraine therapy: do doctors understand what patients with migraine want from therapy?Headache39Suppl 2S206
   Google Scholar
• LiptonRBStewartWFDiamondS2001bPrevalence and burden of migraine in the United States: data from the American Migraine Study IIHeadache416465711554952
   PubMed Web of Science ®Google Scholar
• LiptonRBStewartWFStoneAM2000Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trialJAMA284259960511086366
   PubMed Web of Science ®Google Scholar
• LoderEBrandesJLSilbersteinS2001Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraineHeadache417455311576197
   PubMed Web of Science ®Google Scholar
• LongmoreJHargreavesRJBoulangerCM1997Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocolsFunct Neurol12399127118
   PubMed Web of Science ®Google Scholar
• LongmoreJRazzaqueZShawD1998Comparison of the vaso-constrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptorsBr J Clin Pharmacol46577829862247
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrinkAReekersMBaxWA1998Coronary side-effect potential of current and prospective antimigraine drugsCirculation9825309665056
   PubMed Web of Science ®Google Scholar
• MartinVTGoldsteinJA2005Evaluating the safety and tolerability profile of acute treatments for migraineAm J Med118Suppl 1S3644
   PubMed Web of Science ®Google Scholar
• MathewNTKailasamJGentryP2000Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trialHeadache40464510849042
   PubMed Web of Science ®Google Scholar
• MathewNTKailasamJMeadorsL2004Early treatment of migraine with rizatriptan: a placebo-controlled studyHeadache446697315209688
   PubMed Web of Science ®Google Scholar
• Merck & Co Inc2003Maxalt® (rizatriptan benzoate tablets) and Maxalt-MLT® (rizatriptan benzoate orally disintegrating tablets): United States prescribing informationNew Jersey, USAMerck & Co, Inc
   Google Scholar
• MussonDGBirkKLPanebiancoDL2001Pharmacokinetics of rizatriptan in healthy elderly subjectsInt J Clin Pharmacol Ther394475211680669
   PubMed Web of Science ®Google Scholar
• OkazawaHTsuchidaTPaganiM2006Effects of 5-HT(1B/1D) receptor agonist rizatriptan on cerebral blood flow and blood volume in normal circulationJ Cereb Blood Flow Metab2692815944648
   PubMed Web of Science ®Google Scholar
• PascualJBussoneGHernandezJF2001Comparison of preference for rizatriptan 10-mg wafer vs sumatriptan 50-mg tablet in migraineEur Neurol452758311385269
   PubMed Web of Science ®Google Scholar
• PascualJGarcia-MoncoCRoigC2005Rizatriptan 10-mg wafer vs usual nontriptan therapy for migraine: analysis of return to function and patient preferenceHeadache4511405016178944
   PubMed Web of Science ®Google Scholar
• PascualJVegaPDienerHC2000Comparison of rizatriptan 10 mg vs zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study GroupCephalalgia204556111037741
   PubMed Web of Science ®Google Scholar
• SantanelloNCHartmaierSLEpsteinRS1995Validation of a new quality of life questionnaire for acute migraine headacheHeadache3533077635718
   PubMed Web of Science ®Google Scholar
• SantanelloNCPolisABHartmaierSL1997Improvement in migraine-specific quality of life in a clinical trial of rizatriptanCephalalgia17867729453276
   PubMed Web of Science ®Google Scholar
• SciberrasDGPolvinoWJGertzBJ1997Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonistBr J Clin Pharmacol4349549056052
   PubMed Web of Science ®Google Scholar
• SilbersteinSDfor the US Headache Consortium2000Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology557546210993991
   PubMed Web of Science ®Google Scholar
• SilbersteinSDMassiouHLe JeunneC2000Rizatriptan in the treatment of menstrual migraineObstet Gynecol962374210908770
   PubMed Web of Science ®Google Scholar
• SilbersteinSDMassiouHMcCarrollKA2002Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term dataHeadache429172312390621
   PubMed Web of Science ®Google Scholar
• SnowVWeissKWallEM2002Pharmacologic management of acute attacks of migraine and prevention of migraine headacheAnn Intern Med137840912435222
   PubMed Web of Science ®Google Scholar
• SperlingBTfelt-HansenP1995Lack of effect of MK-462 on cerebral blood flow in manCephalalgia15Suppl 14206 Abstract p5
   Google Scholar
• TeallJTuchmanMCutlerN1998Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study GroupHeadache3828179595867
   PubMed Web of Science ®Google Scholar
• Tfelt-HansenPBlockGDahlofC2000aGuidelines for controlled trials of drugs in migraine: second editionCephalalgia207658611167908
   PubMed Web of Science ®Google Scholar
• Tfelt-HansenPSaxenaPRDahlofC2000bErgotamine in the acute treatment of migraine: a review and European consensusBrain12391810611116
   PubMed Web of Science ®Google Scholar
• Tfelt-HansenPSeidelinKStepanavageM2002The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjectsBr J Clin Pharmacol54384412100223
   PubMed Web of Science ®Google Scholar
• Tfelt-HansenPTeallJRodriguezF1998Oral rizatriptan vs oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study GroupHeadache387485511284463
   PubMed Web of Science ®Google Scholar
• VisserWHTerwindtGMReinesSA1996Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study GroupArch Neurol53113278912486
   PubMed Web of Science ®Google Scholar
• VisserWHWinnerPStrohmaierK2004Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studiesHeadache44891915447698
   PubMed Web of Science ®Google Scholar
• VollonoCCapuanoAMeiD2005Multiple attack study on the available triptans in Italy vs placeboEur J Neurol125576315958097
   PubMed Web of Science ®Google Scholar
• VyasKPHalpinRAGeerLA2000Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humansDrug Metab Dispos28899510611145
   PubMed Web of Science ®Google Scholar
• WilliamsonDJHillRGShepheardSL2001The anti-migraine 5-HT1B/1D agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigsBr J Pharmacol13310293411487512
   PubMed Web of Science ®Google Scholar
• WilliamsonDJShepheardSLHillRG1997The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasationEur J Pharmacol3286149203569
   PubMed Web of Science ®Google Scholar
• WinnerPLewisDVisserWH2002Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled studyHeadache42495512005275
   PubMed Web of Science ®Google Scholar
• ZhangLHayJW2005Cost-effectiveness analysis of rizatriptan and sumatriptan vs Cafergot® in the acute treatment of migraineCNS Drugs196354215984898
   PubMed Web of Science ®Google Scholar